Professional development Vacancies

Draft conclusions

16.01.2024 Updated 16.10.2026 32899 views

In accordance with the resolution of the Cabinet of Ministers of Ukraine of 22 December 2023 No. 1365 “On Amendments to the Resolution of the Cabinet of Ministers of Ukraine of 23 December 2020 No. 1300 ‘On Approval of the Procedure for Conducting State Health Technology Assessment’”, from the date the draft conclusion of the authorized body is published on its website, the applicant, as well as other individuals or legal entities, have the right, within 14 calendar days, to submit comments on the draft conclusion of the authorized body regarding the declared medical technology to the postal address and/or the e-mail address dec@dec.gov.ua. All comments on the draft conclusion of the authorized body will be published

Date:
16.10.2026
INN:
Емпагліфлозин/Empagliflozin
Claimed indication for medical use:
Treatment of chronic heart failure in adult patients with reduced left ventricular ejection fraction.
Draft conclusion:
Проект висновку уповноваженого органу з державної ОМТ емпагліфлозин від 15.10.2026
Comments received on the draft conclusion:
Date:
04.09.2026
INN:
Vilanterol and umeclidinium bromide/Vilanterol and umeclidinium bromide
Claimed indication for medical use:
For maintenance bronchodilator therapy to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) group B according to the GOLD classification.
Draft conclusion:
Проект висновку з державної ОМТ умеклідиніуму бромід/вілантерол (АНОРО ЕЛЛІПТА) від 02.09.2026
Comments received on the draft conclusion:
No comments received
Date:
25.08.2026
INN:
Etelcalcetide
Claimed indication for medical use:
For the treatment of secondary hyperparathyroidism in adult patients with chronic kidney failure who are on hemodialysis.
Draft conclusion:
Проект висновку з державної ОМТ етелкальцетид (ПАРСАБІВ) від 25.08.2026
Comments received on the draft conclusion:
No comments received
Date:
19.08.2026
INN:
Crovalimab/crovalimab
Claimed indication for medical use:
Treatment of adults and children aged 12 years and older weighing 40 kg or more with paroxysmal nocturnal hemoglobinuria with hemolysis and clinical symptoms indicating high disease activity.
Draft conclusion:
Проект висновку з державної ОМТ лікарського засобу кровалімаб (ТН ПІАСКАЙ) від 18.08.2026
Comments received on the draft conclusion:
No comments received
Date:
31.07.2026
INN:
Durvalumab/Durvalumab
Claimed indication for medical use:
For the treatment of adult patients with unresectable stage III NSCLC with PD-L1 expression ≥ 1%, whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Draft conclusion:
Проект висновку з державної ОМТ дурвалумаб (ІМФІНЗІ) від 31.07.2026
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ дурвалумаб
Date:
07.08.2026
INN:
Edoxaban/edoxaban
Claimed indication for medical use:
Prevention of stroke in adult patients with non-valvular atrial fibrillation and one or more risk factors, such as congestive heart failure, arterial hypertension, diabetes mellitus, prior stroke or transient ischemic attack, age from 75 years.
Draft conclusion:
Проект висновку з державної ОМТ лікарського засобу едоксабан (ТН ЕДОКСАКОРД) від 05.08.2026
Comments received on the draft conclusion:
no comments received
Date:
29.07.2026
INN:
Faricimab/Faricimab
Claimed indication for medical use:
Treatment of diabetic macular edema involving the fovea center in adult patients with type 1 or 2 diabetes mellitus
Draft conclusion:
Проект висновку з державної ОМТ фарицимаб (ВАБІСМО) від 28.07.2026
Comments received on the draft conclusion:
No comments received
Date:
29.06.2026
INN:
Darolutamide /Darolutamid
Claimed indication for medical use:
treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastases (PSA-DT < 10 months) in combination with ADT.
Draft conclusion:
Проект висновку з державної ОМТ даролутамід (НУБЕКА) від 26.06.2026
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ даролутамід
Date:
09.06.2026
INN:
Valsartan and sacubitril/(valsartan and sacubitril)
Claimed indication for medical use:
Treatment of chronic heart failure in adult patients with reduced left ventricular ejection fraction.
Draft conclusion:
Проект висновку уповноваженого органу з державної ОМТ валсартан і сакубітрил від 08.06.2026
Comments received on the draft conclusion:
No comments received
Date:
03.06.2026
INN:
Daratumumab
Claimed indication for medical use:
Use of the medicinal product Darzalex® as part of combination therapy with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one line of therapy.
Draft conclusion:
Проект висновку з державної ОМТ даратумумаб (ДАРЗАЛЕКС) від 02.06.2025
Comments received on the draft conclusion:
No comments received
Date:
19.05.2026
INN:
Tobramycin/Tobramycin
Claimed indication for medical use:
Treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis
Draft conclusion:
Проект висновку з державної ОМТ тобраміцин (БРАМІТОБ) від 19.05.2026
Comments received on the draft conclusion:
No comments received
Date:
14.05.2026
INN:
Pembrolizumab
Claimed indication for medical use:
Treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant therapy, followed by adjuvant monotherapy after surgery
Draft conclusion:
Проект висновку з державної ОМТ пембролізумаб (КІТРУДА) від 12.05.2025.
Comments received on the draft conclusion:
No comments received
Date:
27.02.2026
INN:
Selumetinib/Selumetinib
Claimed indication for medical use:
The medicinal product Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform 2 neurofibromas (PN) in pediatric patients aged 3 years and older with neurofibromatosis type 1 (NF1).
Draft conclusion:
Проект висновку з державної ОМТ селуметиніб (КОСЕЛУГО) від 25.02.2026
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ селуметиніб (КОСЕЛУГО) з обґрунтуванням їх врахування або причин неврахування
Date:
12.02.2026
INN:
Trastuzumab deruxtecan/trastuzumab deruxtecan
Claimed indication for medical use:
For the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received one or more therapy regimens based on anti-HER2 agents
Draft conclusion:
Проект висновку з державної ОМТ трастузумаб дерукстекан (ЕНХЕРТУ) від 09.02.2026
Comments received on the draft conclusion:
No comments received
Date:
27.01.2026
INN:
Velmanase alfa (velmanase alfa)
Claimed indication for medical use:
Enzyme replacement therapy for non-neurological manifestations of the disease in patients with mild to moderate alpha-mannosidosis.
Draft conclusion:
Проект висновку з державної ОМТ велманаза альфа (ЛАМЗЕДЕ) від 26.01.2026
Comments received on the draft conclusion:
No comments received
Date:
31.12.2025
INN:
Vigabatrin/Vigabatrin
Claimed indication for medical use:
As monotherapy for infantile spasms (West syndrome) in first-line treatment.
Draft conclusion:
Проект висновку з державної ОМТ вігабатрин (САБРИЛ) від 31.12.2025
Comments received on the draft conclusion:
No comments received
Date:
29.12.2025
INN:
Pembrolizumab
Claimed indication for medical use:
In combination with chemotherapy, indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1), as confirmed by a validated test.
Draft conclusion:
Проект висновку з державної ОМТ пембролізумаб (КІТРУДА) від 29.12.2025
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ пембролізумаб (КІТРУДА)
Date:
12.12.2025
INN:
Emicizumab/Emicizumab
Claimed indication for medical use:
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients older than 12 years with severe hemophilia A without inhibitors to factor VIII and with difficult venous access.
Draft conclusion:
Проект висновку з державної ОМТ еміцизумаб (ГЕМЛІБРА) від 12.12.2025.
Comments received on the draft conclusion:
No comments received
Date:
27.11.2025
INN:
Agalsidase alfa/Agalsidase alfa
Claimed indication for medical use:
Long-term enzyme replacement therapy for patients with a confirmed diagnosis of Fabry disease (alpha-galactosidase deficiency).
Draft conclusion:
Проект висновку з державної ОМТ лікарського засобу агалсидаза альфа (РЕПЛАГАЛ) від 27.11.2025.
Comments received on the draft conclusion:
No comments received
Date:
27.11.2025
INN:
Inclisiran
Claimed indication for medical use:
For the treatment of adult patients with established atherosclerotic cardiovascular disease and primary non-familial hypercholesterolemia and with elevated LDL-C levels despite the use of the maximum tolerated dose of a statin.
Draft conclusion:
Проект висновку з державної ОМТ інклісіран (СІБРАВА) від 27.11.2025
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ інклісіран (СІБРАВА)
Date:
26.11.2025
INN:
Gilteritinib (gilteritinib)
Claimed indication for medical use:
As monotherapy for adult patients with relapsed or refractory acute myeloid leukemia with an FLT3 mutation.
Draft conclusion:
Проект висновку з державної ОМТ гільтеритиніб (КСОСПАТА) від 26.11.2025
Comments received on the draft conclusion:
Date:
20.11.2025
INN:
Tofacitinib citrate
Claimed indication for medical use:
Treatment of adult patients with active ankylosing spondylitis who have not achieved an adequate response to conventional therapy. In this population, initiating the medicinal product is considered for the first time for patients under 65 years of age.
Draft conclusion:
Проект висновку з державної ОМТ тофацитиніб (КСЕЛЬЯНЗ) від 20.11.2025
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ лікарського засобу тофацитинібу цитрат (КСЕЛЬЯНЗ)
Date:
25.09.2025
INN:
Formoterol, glycopyrronium bromide and budesonide
Claimed indication for medical use:
Trixeo Aerosphere is indicated as maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated with a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.
Draft conclusion:
Проект висновку з державної ОМТ формотеролу, глікопіронію броміду та будесоніду (ТРИКСЕО) від 25.09.2025
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ фіксованої потрійної комбінації формотеролу, глікопіронію броміду, будесоніду (Триксео Аеросфера)
Date:
17.09.2025
INN:
Ribociclib
Claimed indication for medical use:
Ribociclib in combination with letrozole for the treatment of postmenopausal women with locally advanced or metastatic breast cancer that is hormone receptor (HR)-positive and HER2-negative (human epidermal growth factor receptor type 2), as initial endocrine therapy or for the treatment of women who have previously received endocrine therapy.
Draft conclusion:
Проект висновку з державної ОМТ рибоцикліб (КІСКАЛІ) від 16.09.2025
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ рибоцикліб (КІСКАЛІ)
Date:
01.09.2025
INN:
Acalabrutinib
Claimed indication for medical use:
Acalabrutinib as monotherapy for the treatment of adult patients with previously untreated chronic lymphocytic leukemia, poor performance status and intolerance/unsuitability of therapy with fludarabine in combination with cyclophosphamide and rituximab (FCR) and bendamustine in combination with rituximab (BR).
Draft conclusion:
Проект висновку з державної ОМТ акалабрутиніб (КАЛКВЕНС) від 01.09.2025
Comments received on the draft conclusion:
No comments received
Date:
20.08.2025
INN:
Ofatumumab
Claimed indication for medical use:
Ofatumumab for the treatment of adult patients with active relapsing-remitting multiple sclerosis who have previously received glatiramer acetate, interferon beta, or dimethyl fumarate but whose disease activity persists.
Draft conclusion:
Проект висновку з державної ОМТ офатумумаб (БОНСПРІ) від 20.08.2025.
Comments received on the draft conclusion:
No comments received
Date:
04.08.2025
INN:
Ixazomib
Claimed indication for medical use:
Ixazomib in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have previously received at least 2 prior lines of therapy and have retained sensitivity to lenalidomide.
Draft conclusion:
Проект висновку з державної ОМТ іксазоміб (НІНЛАРО) від 04.08.2025
Comments received on the draft conclusion:
No comments received
Date:
23.06.2025
INN:
Normal human immunoglobulin
Claimed indication for medical use:
Treatment of the steroid-resistant population of patients with chronic inflammatory demyelinating neuropathy with ineffectiveness of/contraindications to plasmapheresis, for whom there is no treatment alternative other than placebo/medical rehabilitation
Draft conclusion:
Проект висновку з державної ОМТ імуноглобулін людини нормальний (БІОВЕН) від 23.06.2025
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ імуноглобулін людини нормальний (БІОВЕН)
Date:
20.06.2025
INN:
Ribociclib
Claimed indication for medical use:
In combination with an aromatase inhibitor and a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of pre- or perimenopausal women with locally advanced or metastatic breast cancer that is HR-positive (hormone receptor) and HER2-negative (human epidermal growth factor receptor type 2) as initial endocrine therapy, or for the treatment of women who have previously received endocrine therapy.
Draft conclusion:
Проект висновку з державної ОМТ рибоцикліб (КІСКАЛІ) від 20.06.2025
Comments received on the draft conclusion:
No comments received
Date:
12.06.2025
INN:
Pertuzumab/trastuzumab
Claimed indication for medical use:
Pertuzumab and trastuzumab in combination with docetaxel are indicated for adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease
Draft conclusion:
Проект висновку з державної ОМТ пертузумаб/трастузумаб (ФЕСГО) від 12.06.2025
Comments received on the draft conclusion:
No comments received
Date:
02.06.2025
INN:
Lanadelumab
Claimed indication for medical use:
For routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older
Draft conclusion:
Проект висновку з державної ОМТ ланаделумаб (ТАКЗАЙРО) від 02.06.2025 на 47 арк
Comments received on the draft conclusion:
No comments received
Date:
28.05.2025
INN:
Acalabrutinib (acalabrutinib)
Claimed indication for medical use:
Indicated as monotherapy for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one course of therapy.
Draft conclusion:
Проект висновку з державної ОМТ акалабрутиніб (КАЛКВЕНС) від 26.05.2025
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ акалабрутиніб (КАЛКВЕНС)
Date:
07.04.2025
INN:
Polatuzumab vedotin
Claimed indication for medical use:
In combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
Draft conclusion:
Проект висновку з державної ОМТ полатузумаб ведотин (ПОЛАЙВІ) від 04.04.2025
Comments received on the draft conclusion:
No comments received
Date:
28.02.2025
INN:
Rabbit antithymocyte globulin
Claimed indication for medical use:
Immunosuppression in transplantation: prevention of graft rejection (in kidney transplantation)
Draft conclusion:
Проект висновку з державної ОМТ антитимоцитарний глобулін кролячий (ТИМОГЛОБУЛІН) від 28.02.2025
Comments received on the draft conclusion:
No comments received
Date:
31.01.2025
INN:
Fremanezumab
Claimed indication for medical use:
Preventive therapy for adult patients with chronic migraine after failure of two lines of preventive therapy
Draft conclusion:
Проект висновку з державної ОМТ фреманезумаб (АДЖОВІ) від 30.01.2025
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ фреманезумаб (АДЖОВІ)
Date:
24.12.2024
INN:
Enzalutamide
Claimed indication for medical use:
Treatment of non-metastatic castration-resistant prostate cancer in adult men at high risk of progression.
Draft conclusion:
Проект висновку з державної ОМТ ензалутамід (КСТАНДІ) від 23.12.2024
Comments received on the draft conclusion:
No comments received
Date:
24.12.2024
INN:
Atezolizumab
Claimed indication for medical use:
Non-small cell lung cancer. Adjuvant treatment as monotherapy after resection and platinum-based chemotherapy of adult patients with stage IIIIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥ 1% of tumor cells.
Draft conclusion:
Проект висновку з державної ОМТ атезолізумаб (ТЕЦЕНТРИК) від 23.12.2024.
Comments received on the draft conclusion:
No comments received
Date:
04.12.2024
INN:
Brentuximab vedotin
Claimed indication for medical use:
In combination with cyclophosphamide, doxorubicin and prednisone (CHP), indicated for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
Draft conclusion:
Проект висновку з державної ОМТ брентуксимабу ведотин (АДЦЕТРИС) від 03.12.2024
Comments received on the draft conclusion:
No comments received
Date:
26.11.2024
INN:
Pegvisomant
Claimed indication for medical use:
Treatment of acromegaly in adult patients in whom surgery and/or radiotherapy, and subsequent SSA therapy, have not produced an adequate effect (namely, normalization of serum IGF-1 levels) or were inappropriate.
Draft conclusion:
Проект висновку з державної ОМТ пегвісомант (СОМАВЕРТ) від 25.11.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ пегвісомант (СОМАВЕРТ)
Date:
22.11.2024
INN:
Enzalutamide
Claimed indication for medical use:
Treatment of metastatic castration-resistant prostate cancer in adult men with disease progression during or after chemotherapy that included docetaxel
Draft conclusion:
Проект висновку з державної ОМТ ензалутамід (КСТАНДІ) від 20.11.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ ензалутамід (КСТАНДІ)
Date:
12.11.2024
INN:
Palbociclib
Claimed indication for medical use:
Advanced breast cancer (hereinafter – BC) HR(+), HER2(-), stage IV, without life-threatening visceral involvement. Postmenopausal patients who have not received prior treatment for metastases.
Draft conclusion:
Проект висновку з державної ОМТ палбоцикліб (ІБРАНС) від 11.11.2024
Comments received on the draft conclusion:
No comments received
Date:
29.10.2024
INN:
Cetuximab
Claimed indication for medical use:
Treatment of patients with RAS wild-type metastatic colorectal cancer expressing epidermal growth factor receptor EGFR in combination with irinotecan-based chemotherapy or prolonged infusions of 5-fluorouracil/folinic acid and oxaliplatin as first-line therapy.
Draft conclusion:
Проект висновку з державної ОМТ цетуксимаб (ЕРБІТУКС) від 28.10.2024
Comments received on the draft conclusion:
No comments received
Date:
08.10.2024
INN:
Dabrafenib, trametinib
Claimed indication for medical use:
Dabrafenib is prescribed in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma whose cells have a BRAF V600 mutation.
Draft conclusion:
Проект висновку з державної ОМТ дабрафеніб, траметиніб (ТАФІНЛАР®, МЕКІНІСТ) від 08.10.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ дабрафеніб, траметиніб (ТАФІНЛАР®, МЕКІНІСТ)
Date:
26.08.2024
INN:
Inotuzumab ozogamicin
Claimed indication for medical use:
Treatment of adult patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukemia. If patients have the Philadelphia chromosome-positive relapsed or refractory B-cell acute lymphoblastic leukemia, they must already be resistant to at least one tyrosine kinase inhibitor.
Draft conclusion:
Проект висновку з державної ОМТ інотузумабу озогаміцин (БЕСПОНЗА) від 26.08.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ інотузумабу озогаміцин (Беспонза)
Date:
11.07.2024
INN:
Venetoclax
Claimed indication for medical use:
In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic (lymphoid) leukemia (CLL)
Draft conclusion:
Проект висновку з державної ОМТ венетоклакс (ВЕНКЛІКСТО) від 11.07.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ венетоклакс (ВЕНКЛІКСТО)
Date:
13.05.2024
INN:
Ruxolitinib
Claimed indication for medical use:
Treatment of splenomegaly-related disorders or symptoms of primary myelofibrosis (also known as chronic idiopathic myelofibrosis) in adult patients, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis
Draft conclusion:
Проект висновку з державної ОМТ руксолітиніб (ДЖАКАВІ) від 13.05.2024
Comments received on the draft conclusion:
No comments received
Date:
01.05.2024
INN:
Formoterol and beclometasone
Claimed indication for medical use:
For the regular treatment of bronchial asthma where use of a combination product (inhaled glucocorticosteroid and long-acting beta2-agonist) is appropriate, in patients whose symptoms are not adequately controlled with inhaled glucocorticosteroids and rapid-acting beta2-agonists used as needed.
Draft conclusion:
Проект висновку з державної ОМТ формотерол та бекламетазон (ФОСТЕР) від 01.05.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ формотерол та беклометазон (ФОСТЕР)
Date:
26.04.2024
INN:
Nintedanib
Claimed indication for medical use:
Treatment of idiopathic pulmonary fibrosis (IPF) in adults
Draft conclusion:
Проект висновку з державної ОМТ нінтеданіб (ОФЕВ) від 25.04.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ нінтеданіб (ОФЕВ)
Date:
25.03.2024
INN:
Rivaroxaban
Claimed indication for medical use:
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.
Draft conclusion:
Проект висновку з державної ОМТ ривароксабан (КСАРЕЛТО) від 22.03.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ ривароксабан (КСАРЕЛТО)
Date:
11.03.2024
INN:
Trifluridine/tipiracil
Claimed indication for medical use:
Monotherapy treatment of adult patients with metastatic colorectal cancer who have previously been treated with, or are not considered candidates for, available therapies, including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, as well as anti-VEGF and anti-EGFR agents
Draft conclusion:
Проект висновку з державної ОМТ трифлуридин/типірацил (ЛАНСУРФ) від 08.03.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ трифлуридин/типірацил (ЛАНСУРФ)
Date:
23.02.2024
INN:
Risdiplam
Claimed indication for medical use:
Treatment of 5q-associated spinal muscular atrophy (SMA) in patients aged 2 months and older
Draft conclusion:
Проект висновку з державної ОМТ рисдиплам (ЕВРІСДІ) від 22.02.2024
Comments received on the draft conclusion:
No comments received
Date:
26.01.2024
INN:
Dapagliflozin
Claimed indication for medical use:
Treatment of chronic kidney disease
Draft conclusion:
Проект висновку з державної ОМТ дапагліфлозин (ФОРКСІГА) від 25.01.2024
Comments received on the draft conclusion:
Зауваження які надійшли до проекту висновку з Державної ОМТ
Date:
19.01.2024
INN:
Rivaroxaban
Claimed indication for medical use:
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation at risk of stroke according to the CHA2DS2-VASc score ≥1 for men and ≥2 for women
Draft conclusion:
Проект висновку з державної ОМТ ривароксабан (КСАРЕЛТО) від 19.01.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ ривароксабан (КСАРЕЛТО)
Date:
16.01.2024
INN:
Tofacitinib citrate
Claimed indication for medical use:
Treatment of active polyarticular juvenile idiopathic arthritis (JIA) in adults and children weighing more than 40 kg
Draft conclusion:
Проект висновку з державної ОМТ тофацитинібу цитрат (КСЕЛЬЯНЗ) від 15.01.2024
Comments received on the draft conclusion:
Зауваження, які надійшли до проекту висновку з державної ОМТ тофацитинібу цитрат (КСЕЛЬЯНЗ)